Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1Liver Neoplasms 1

Interventions

pembrolizumab 1fludarabine phosphate 1Whole-Body Irradiation 1Vorinostat 1Valganciclovir 1Tomography, X-Ray Computed 1Therapeutics 1Tacrolimus 1Sirolimus 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Methotrexate 1Melphalan 1IMC-001 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Etoposide 1Cyclosporine 1Cyclophosphamide 1Cholecalciferol 1Busulfan 1Azacitidine 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Extranodal NK-T-Cell × IMC-001 × Clear all
NCT04414163 2026-04-24

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

ImmuneOncia Therapeutics Inc.

Phase 2 Active not recruiting
23 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡